Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bipolar affective disorder is a common severe illness which is associated with a significant morbidity and mortality. The area of pharmacotherapy for bipolar disorders is an exciting one with a number of recent new developments. This article summarises the current state of evidence regarding the efficacy of lithium, valproate and carbamazepine for the treatment of bipolar disorders and also highlights the emerging role of the atypical antipsychotics and newer anticonvulsants.

Original publication




Journal article


Expert Rev Neurother

Publication Date





239 - 248